metastases

Prostate cancer. Illustration: depositphotos.com

Making drug resistance a weak point in metastatic prostate cancer

A new computational tool, SpotNeoMet, developed at the Weizmann Institute, detects resistance mutations that recur in many patients and create neoantigens – a possible target for “precision” immunotherapy for broad patient groups
The D'20 peptide inhibits the cancer-causing enzyme MMP7. The image was prepared using DALEE and is not a scientific image

A new stable and selective inhibitor of a cancer-causing enzyme has been revealed in a new study

Researchers from the Hebrew University, the Weizmann Institute and the University of Tokyo have developed an innovative peptide that suppresses the activity of the MMP7 enzyme associated with cancer progression, with the potential for targeted therapies in aggressive cancers.
Thyroid cancer cells. Source: NASA / Team Daniela Grimm.

Carcinogenic groups

When the level of PYK2 is lowered through genetic engineering, metastatic breast cancer cells (left) revert to a non-invasive state (right). In this state they come into contact with each other and take the form of healthy tissue cells. Source: Weizmann Institute.

On the occasion of International Women's Day 2016: three goals

From the right: Benny Shapiro, Dr. Nancy Gebert and Prof. Avri Ben-Zev. Standing behind: Anna Shoab and Gal Haz. "The Good Hero". Photo: Weizmann Institute

The double life of the cancer gene